8-K: Scholar Rock Reports Q1 2024 Financial Results and Provides Business Update

Scholar Rock announced its first quarter 2024 financial results, highlighted by progress in its SMA and cardiometabolic programs, and a cash runway extending into the second half of 2025.

Summary

• Scholar Rock reported a net loss of $56.9 million, or $0.59 per share, for the first quarter of 2024, compared to a net loss of $39.4 million, or $0.49 per share, for the same period in 2023.
• The company's research and development expenses increased to $43.1 million in Q1 2024 from $29.7 million in Q1 2023, primarily due to higher clinical trial and research study costs.
• General and administrative expenses also rose to $15.3 million in Q1 2024 from $10.8 million in Q1 2023, driven by increased employee-related costs.
• As of March 31, 2024, Scholar Rock had $238 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2025.
• The company is on track to report topline data from its pivotal Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy (SMA) in the fourth quarter of 2024.
• A Phase 2 proof-of-concept trial evaluating apitegromab in obesity is set to begin in June 2024.
• Preclinical data for SRK-439, a myostatin inhibitor for obesity, will be presented at the American Diabetes Association conference in June 2024.
• Updated clinical data for SRK-181, an immuno-oncology drug, will be presented at the American Society of Clinical Oncology meeting in May/June 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the strong cash position, but tempered by the increased net loss and expenses. The company is making progress but faces financial challenges.

Positives

• The company has a strong cash position of $238 million, providing a runway into the second half of 2025.
• The Phase 3 SAPPHIRE trial for apitegromab in SMA is progressing as planned, with topline data expected in Q4 2024.
• The initiation of a Phase 2 trial for apitegromab in obesity expands the potential applications of the drug.
• The selection of SRK-439 and SRK-181 data for presentations at major medical conferences highlights the progress of these programs.
• The company is actively exploring the potential of myostatin inhibition in both SMA and obesity.

Negatives

• The company reported a net loss of $56.9 million for the first quarter of 2024, which is an increase compared to the $39.4 million loss in the same period of 2023.
• Research and development expenses increased significantly to $43.1 million in Q1 2024, up from $29.7 million in Q1 2023.
• General and administrative expenses also increased to $15.3 million in Q1 2024, compared to $10.8 million in Q1 2023.
• The company did not record any revenue for the quarter ended March 31, 2024 or for the quarter ended March 31, 2023.

Risks

• Clinical trial results may not be consistent with previous data, potentially impacting the approval and commercialization of apitegromab.
• The company's ability to obtain regulatory approvals for its drug candidates is not guaranteed.
• Competition from other companies developing similar treatments could affect Scholar Rock's market position.
• The company's dependence on third parties for development and manufacturing could lead to delays or supply issues.
• The company may need to raise additional capital in the future to support its operations and development programs.

Future Outlook

The company expects its current cash position to fund operations into the second half of 2025 and is focused on executing its clinical programs, particularly the Phase 3 SAPPHIRE trial and the Phase 2 trial for obesity. They are also advancing their preclinical programs and preparing for potential commercial launch of apitegromab in SMA in 2025.

Management Comments

• Scholar Rock is now only two quarters away from reporting topline data for our pivotal Phase 3 SAPPHIRE trial, which has the potential to build upon the promising data generated from our prior Phase 2 trial, said Jay Backstrom, M.D., MPH, President & Chief Executive Officer of Scholar Rock.
• As we look towards a potential commercial launch of apitegromab in SMA in 2025, were thrilled to be on the precipice of delivering a new class of treatment with potential to meaningfully impact people living with SMA.
• In parallel, we continue to make important progress with our cardiometabolic program.
• We are acutely focused on execution in 2024 as we prepare for the pivotal Phase 3 readout of apitegromab in SMA and continue to progress our cardiometabolic program through clinical development.
• Our cash position enables us to reach multiple upcoming key milestones as we prepare for our next phase of growth, said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock.

Industry Context

Scholar Rock is operating in the competitive biopharmaceutical space, focusing on innovative treatments for SMA, cardiometabolic disorders, and cancer. The company's focus on myostatin inhibition and TGF-beta superfamily biology positions it within a growing area of research and development. The company is competing with other companies developing treatments for SMA and obesity, including those using gene therapies and other approaches.

Comparison to Industry Standards

• Scholar Rock's focus on myostatin inhibition is a unique approach in the SMA space, differentiating it from gene therapies like Zolgensma (Novartis) and SMN splicing modifiers like Spinraza (Biogen) and Evrysdi (Roche).
• In the obesity space, Scholar Rock is exploring a novel approach by combining myostatin inhibition with GLP-1 agonists, which is different from the current focus on GLP-1 agonists alone, such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly).
• The company's cash runway into the second half of 2025 is a positive sign, but it will need to continue to manage expenses and potentially raise additional capital to support its long-term development goals.
• The increase in R&D expenses is typical for a company in clinical development, but the increase in G&A expenses may need to be monitored closely.
• The company's net loss is consistent with other clinical-stage biotech companies that are investing heavily in research and development.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the clinical progress and cash runway.
• Employees may be impacted by the increased employee-related costs and the company's overall financial performance.
• Patients with SMA and obesity may benefit from the potential development of new treatments.
• The company's suppliers and creditors may be impacted by the company's financial performance and future funding needs.

Next Steps

• Report topline data from the Phase 3 SAPPHIRE trial in Q4 2024.
• Initiate the Phase 2 proof-of-concept trial for apitegromab in obesity in June 2024.
• Present preclinical data for SRK-439 at the American Diabetes Association conference in June 2024.
• Present updated clinical data for SRK-181 at the ASCO Annual Meeting in May/June 2024.
• File an IND for SRK-439 for the treatment of obesity in 2025.
• Hold an Investor & Analyst Day on May 22, 2024.

Key Dates

Keywords

Spinal Muscular Atrophy, SMA, Apitegromab, Myostatin Inhibitor, Obesity, SRK-439, SRK-181, Clinical Trial, Biopharmaceutical, Phase 3, Phase 2, Cardiometabolic, Immuno-Oncology